Hiccup For Evotec As Bayer Pulls Plug On Chronic Cough Drug
German Major Discontinuing Development Of Eliapixant
Executive Summary
With the future of eliapixant in doubt, Shinogi's sivopixant struggling and a recent FDA rejection for Merck & Co's chronic cough drug gefapixant, Bellus Health's BLU-5937 looks to have emerged as a best-in-class agent in the P2X3 space.
You may also be interested in...
Finance Watch: Theravance Eliminates Debt In $1.1bn Trelegy Royalty Sell-Off
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
Merck & Co's Gefapixant Effective In Refractory Cough, But Taste Concerns Remain
Updated results from two Merck & Co Phase III studies, COUGH-1 and COUGH-2, confirm the drug’s efficacy in reducing the frequency of refractory cough and its association with taste disturbances.